Abstract 17P
Background
In Australia, Indigenous people are natives and custodians of land. The mortality risk is more than double in Indigenous breast cancer women as compared to non- Indigenous women but carries lower incidence risk. Between 2001 and 2010 Indigenous Western Australian women who developed breast cancer were four times more likely to die of the disease than non-Indigenous women of the same age. The data is scarce but many factors are being studied. The effect of remoteness on mortality of indigenous women still needed to be established. The aim is to analyse remoteness as a factor causing effect on survival in Indigenous breast cancer women.
Methods
The data is collected retrospectively from Western Australian cancer Registry mostly, among other sources. A cohort of 100 patients was selected from database including half of indigenous and half non-indigenous women (1:1). At time of writing, 37 Indigenous and 33 Non–Indigenous breast cancer women data was available. The data collected, to analyze the median survival time (months) of patients with respect to Distance (Metropolitan vs Rural) and Indigenous & Non-Indigenous status.
Results
In survival analysis, it has been observed that both indigenous and non-indigenous who live in metropolitan showed better 10 year survival ; 184 months while who were in rural area showed reduced median survival time 130 months and differences among them was found to be significant (p = 0.03), suggesting better survival was associated with patients who live in metropolitan area. However, on analyzing the survival of Indigenous patients with respect to distance, it wasn’t statistically significant (p = 0.19) but still showed higher median survival for patients living in metropolitan area (153 months) as compared to remote rural areas (110 months). Further analyzing indigenous breast cancer patients outcomes with respect to metro area (153 months), 1000km or less and greater then 1000km (87 months); higher survival benefit trend for patient’s living close to metro area.
Conclusions
The data suggest that the Indigenous breast cancer women have inferior survival outcomes with respect to distance from metropolitan area, highlighting a strong co-relation of remoteness and survival disadvantage.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
A. Khan, A. Redfern.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
511P - Phase II trial of carboplatin, nab-paclitaxel and bevacizumab for advanced non-squamous non-small cell lung cancer (CARNAVAL study; TORG1424/OLCSG1402)
Presenter: Toshio Kubo
Session: Poster display session
Resources:
Abstract
485P - A real-world experience of first-line afatinib in Korean patients with EGFR-mutant non-small cell lung cancer
Presenter: Seong Hoon Yoon
Session: Poster display session
Resources:
Abstract
522P - Weekly nab-PTX and weekly PTX for relapsed small cell lung cancer
Presenter: Hajime Oi
Session: Poster display session
Resources:
Abstract
512P - A phase I and extension study of S-1 and carboplatin for previously untreated patients aged 75 years or more with advanced non-small cell lung cancer
Presenter: Hisao Imai
Session: Poster display session
Resources:
Abstract
497P - Real-word efficacy of osimertinib in patients with metastatic EGFRm NSCLC: An interim analysis from a multi-center study in China
Presenter: Xiangyun Ye
Session: Poster display session
Resources:
Abstract
507P - Immune checkpoint inhibitors for patients acquired resistance to tyrosine kinase inhibitors with EGFR mutated non-small cell lung cancer: A multicenter retrospective study
Presenter: Takeshi Uenami
Session: Poster display session
Resources:
Abstract
516P - Clinical outcomes in elderly patients with advanced non-small cell lung cancer: A prospective multicenter study of the National Hospital Organization in Japan
Presenter: Masahiro Shimada
Session: Poster display session
Resources:
Abstract
486P - Phase II study of low-dose afatinib maintenance treatment for patients with EGFR-mutated non-small cell lung cancer (NJLCG1601)
Presenter: Mami Morita
Session: Poster display session
Resources:
Abstract
515P - Polypharmacy as a prognostic factor in elderly patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors
Presenter: Taiki Hakozaki
Session: Poster display session
Resources:
Abstract
518P - Real world prospective clinical impact of finding actionable genomic alterations by plasma cell-free DNA next generation sequencing in advanced non-small cell lung cancer
Presenter: Beung chul Ahn
Session: Poster display session
Resources:
Abstract